Mupiban

When are you taking this medicine? Empty stomach Before food After food With a meal

Mupiban uses

• Indications and usage
• Dosage and administration
• Dosage forms and strengths
• Contraindications
• Warnings and precautions
• Adverse reactions
• Use in specific populations
• Description
• Clinical pharmacology
• Nonclinical toxicology
• Clinical studies
• References
• How supplied/storage and handling
• Patient counseling information
• Patient information
• Mupiban reviews

1 INDICATIONS AND USAGE

Mupiban ointment is indicated for the topical treatment of impetigo due to susceptible isolates of Staphylococcus aureus (S. aureus) and Streptococcus pyogenes (S. pyogenes).

Mupirocinointment is an RNA synthetase inhibitor antibacterial indicated for the topical treatment of impetigo due to susceptible isolates of Staphylococcus aureus and Streptococcus pyogenes. (1)

2 DOSAGE AND ADMINISTRATION

• For Topical Use Only.
• Apply a small amount of Mupiban ointment, with a cotton swab or gauze pad, to the affected area 3 times daily for up to 10 days.
• Cover the treated area with gauze dressing if desired.
• Re-evaluate patients not showing a clinical response within 3 to 5 days.
• Mupiban ointment is not for intranasal, ophthalmic, or other mucosal use [see Warnings and Precautions ( 5.2, 5.6)].
• Do not apply Mupiban ointment concurrently with any other lotions, creams, or ointments [see Clinical Pharmacology ( 12.3)].

• For Topical Use Only. (2)
• Apply a small amount of Mupiban ointment, with a cotton swab or gauze pad, to the affected area 3 times daily for up to 10 days. (2)
• Re-evaluate patients not showing a clinical response within 3 to 5 days. (2)
• Not for intranasal, ophthalmic, or other mucosal use. (2)

3 DOSAGE FORMS AND STRENGTHS

Each gram of Mupiban Ointment USP contains 20 mg Mupiban, USP in a water-miscible ointment base supplied in 22-gram tubes.

• Ointment: Each gram contains 20 mg Mupiban, USP in a water-miscible ointment base supplied in 22-gram tubes. (3)

4 CONTRAINDICATIONS

Mupiban ointment is contraindicated in patients with known hypersensitivity to Mupiban or any of the excipients of Mupiban ointment.

• Known hypersensitivity to Mupiban or any of the excipients of Mupiban ointment. (4)

5 WARNINGS AND PRECAUTIONS

• Severe Allergic Reactions: Anaphylaxis, urticaria, angioedema, and generalized rash have been reported in patients treated with formulations of Mupiban, including Mupiban ointment.
• Eye Irritation: Avoid contact with eyes. (5.2)
• Local Irritation: Discontinue in the event of sensitization or severe local irritation. (5.3)
• Clostridium difficile-Associated Diarrhea (CDAD): If diarrhea occurs, evaluate patients for CDAD. (5.4)
• Potential for Microbial Overgrowth: Prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi. (5.5)
• Risk Associated with Mucosal Use: Mupiban ointment is not formulated for use on mucosal surfaces. A separate formulation, BACTROBAN nasal ointment, is available for intranasal use. (5.6)
• Risk of Polyethylene Glycol Absorption: Mupiban ointment should not be used where absorption of large quantities of polyethylene glycol is possible, especially if there is evidence of moderate or severe renal impairment. (5.7)
• Risk Associated with Use at Intravenous Sites: Mupiban ointment should not be used with intravenous cannulae or at central intravenous sites because of the potential to promote fungal infections and antimicrobial resistance. (5.8)

5.1 Severe Allergic Reactions

Systemic allergic reactions, including anaphylaxis, urticaria, angioedema, and generalized rash, have been reported in patients treated with formulations of Mupiban, including Mupiban ointment .

5.2 Eye Irritation

Avoid contact with the eyes. In case of accidental contact, rinse well with water.

5.3 Local Irritation

In the event of a sensitization or severe local irritation from Mupiban ointment, usage should be discontinued, and appropriate alternative therapy for the infection instituted.

5.4 Clostridium difficile-Associated Diarrhea

Clostridium difficile-associated diarrhea has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

5.5 Potential for Microbial Overgrowth

As with other antibacterial products, prolonged use of Mupiban ointment may result in overgrowth of nonsusceptible microorganisms, including fungi .

5.6 Risk Associated with Mucosal Use

Mupiban ointment is not formulated for use on mucosal surfaces. Intranasal use has been associated with isolated reports of stinging and drying. A separate formulation, BACTROBAN^® nasal ointment, is available for intranasal use.

5.7 Risk of Polyethylene Glycol Absorption

Polyethylene glycol can be absorbed from open wounds and damaged skin and is excreted by the kidneys. In common with other polyethylene glycol-based ointments, Mupiban ointment should not be used in conditions where absorption of large quantities of polyethylene glycol is possible, especially if there is evidence of moderate or severe renal impairment.

5.8 Risk Associated with Use at Intravenous Sites

Mupiban ointment should not be used with intravenous cannulae or at central intravenous sites because of the potential to promote fungal infections and antimicrobial resistance.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

• Severe Allergic Reactions
• Eye Irritation
• Local Irritation
• Clostridium difficile-Associated Diarrhea

• The most frequent adverse reactions (at least 1%) were burning, stinging or pain, and itching. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888)721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The following local adverse reactions were reported by at least 1% of subjects in connection with the use of Mupiban ointment in clinical trials: burning, stinging, or pain in 1.5% of subjects; itching in 1% of subjects. Rash, nausea, erythema, dry skin, tenderness, swelling, contact dermatitis, and increased exudate were reported in less than 1% of subjects.

6.2 Postmarketing Experience

In addition to adverse reactions reported from clinical trials, the following reactions have been identified during postmarketing use of Mupiban ointment. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal relationship to Mupiban ointment.

Immune System Disorders

Systemic allergic reactions, including anaphylaxis, urticaria, angioedema, and generalized rash [see Warnings and Precautions ( 5.1)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are insufficient human data to establish whether there is a drug-associated risk with Mupiban ointment in pregnant women. Systemic absorption of Mupiban through intact human skin is minimal following topical administration of Mupiban ointment . No developmental toxicity was observed in rats or rabbits treated with Mupiban subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area).

The estimated background risk of major birth defects and miscarriages for the indicated population is unknown. The estimated background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.

Data

Animal Data: Developmental toxicity studies have been performed with Mupiban administered subcutaneously to rats and rabbits at doses up to 160 mg per kg per day during organogenesis. This dose is 22 and 43 times, respectively, the human topical dose (approximately 60 mg Mupiban per day) based on calculations of dose divided by the entire body surface area. Maternal toxicity was observed (body weight loss/decreased body weight gain and reduced feeding) in both species with no evidence of developmental toxicity in rats. In rabbits, excessive maternal toxicity at the high dose precluded the evaluation of fetal outcomes. There was no developmental toxicity in rabbits at 40 mg per kg per day, 11 times the human topical dose based on calculations of dose divided by the entire body surface area.

Mupiban administered subcutaneously to rats in a pre-and postnatal development study (dosed during late gestation through lactation) was associated with reduced offspring viability in the early postnatal period at a dose of 106.7 mg per kg, in the presence of injection site irritation and/or subcutaneous hemorrhaging. This dose is 14 times the human topical dose based on calculations of dose divided by the entire body surface area. The no-observed adverse effect level in this study was 44.2 mg per kg per day, which is 6 times the human topical dose.

8.2 Lactation

Risk Summary

It is not known whether Mupiban is present in human milk, has effects on the breastfed child, or has effects on milk production. However, breastfeeding is not expected to result in exposure of the child to the drug due to the minimal systemic absorption of Mupiban in humans following topical administration of Mupiban ointment [see Clinical Pharmacology ( 12.3)]. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Mupiban ointment and any potential adverse effects on the breastfed child from Mupiban ointment or from the underlying maternal condition.

Clinical Considerations

To minimize oral exposure of the drug to children, a breast and/or nipple being treated with Mupiban ointment should be thoroughly washed prior to breastfeeding.

8.4 Pediatric Use

The safety and effectiveness of Mupiban ointment have been established in the age range of 2 months to 16 years. Use of Mupiban ointment in these age-groups is supported by evidence from adequate and well-controlled trials of Mupiban ointment in impetigo in pediatric subjects studied as a part of the pivotal clinical trials [see Clinical Studies ( 14)].

11 DESCRIPTION

Mupiban Ointment USP, 2% contains the RNA synthetase inhibitor antibacterial, Mupiban, USP. The chemical name is (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4dihydroxy-β-methyl-2H-pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid. The molecular formula of Mupiban, USP is C₂₆H₄₄O₉, and the molecular weight is 500.6. The structural formula of Mupiban, USP is:

Figure 1. Structure of Mupiban, USP

Each gram of Mupiban Ointment USP, 2% contains 20 mg Mupiban, USP in a water-miscible ointment base (polyethylene glycol ointment, N.F.) consisting of polyethylene glycol 400 and polyethylene glycol 3350.

Structure

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Mupiban is an RNA synthetase inhibitor antibacterial .

12.3 Pharmacokinetics

Absorption

Application of ¹⁴C-labeled Mupiban ointment to the lower arm of normal male subjects followed by occlusion for 24 hours showed no measurable systemic absorption (less than 1.1 nanogram Mupiban per milliliter of whole blood). Measurable radioactivity was present in the stratum corneum of these subjects 72 hours after application.

The effect of the concurrent application of Mupiban ointment with other topical products has not been studied [see Dosage and Administration ( 2)].

Elimination

In a trial conducted in 7 healthy adult male subjects, the elimination half-life after intravenous administration of Mupiban was 20 to 40 minutes for Mupiban and 30 to 80 minutes for monic acid.

Metabolism: Following intravenous or oral administration, Mupiban is rapidly metabolized. The principal metabolite, monic acid, demonstrates no antibacterial activity.

Excretion: Monic acid is predominantly eliminated by renal excretion.

12.4 Microbiology

Mupiban is an RNA synthetase inhibitor antibacterial produced by fermentation using the organism Pseudomonas fluorescens.

Mechanism of Action

Mupiban inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl-transfer RNA (tRNA) synthetase.

Mupiban is bactericidal at concentrations achieved by topical administration. Mupiban is highly protein bound (greater than 97%) and the effect of wound secretions on the minimum inhibitory concentrations (MICs) of Mupiban has not been determined.

Resistance

When Mupiban resistance occurs, it results from the production of a modified isoleucyl-tRNA synthetase, or the acquisition of, by genetic transfer, a plasmid mediating a new isoleucyl-tRNA synthetase. High-level plasmid-mediated resistance (MIC ≥512 mcg/mL) has been reported in increasing numbers of isolates of S. aureus and with higher frequency in coagulase-negative staphylococci. Mupiban resistance occurs with greater frequency in methicillin-resistant than methicillin-susceptible staphylococci.

Cross Resistance

Due to its mode of action, Mupiban does not demonstrate cross resistance with other classes of antimicrobial agents.

Antimicrobial Activity

Mupiban has been shown to be active against susceptible isolates of S. aureus and S. pyogenes, both in vitro and in clinical trials [see Indications and Usage ( 1)]. The following in vitro data are available, but their clinical significance is unknown. Mupiban is active against most isolates of Staphylococcus epidermidis.

Susceptibility Test Methods

High-level Mupiban resistance (≥512 mcg/mL) may be determined using standard disk diffusion or broth microdilution tests.^1,2 Because of the occurrence of Mupiban resistance in methicillin-resistant S. aureus (MRSA), it is appropriate to test MRSA populations for Mupiban susceptibility prior to the use of Mupiban using a standardized method. ^3,4,5

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals to evaluate carcinogenic potential of Mupiban have not been conducted.

Results of the following studies performed with Mupiban calcium or Mupiban sodium in vitro and in vivo did not indicate a potential for genotoxicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, Salmonella reversion test (Ames), Escherichia coli mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice.

In a fertility/reproductive performance study (with dosing through lactation), Mupiban administered subcutaneously to male and female rats at doses up to 100 mg per kg per day which is 14 times the human topical dose (approximately 60 mg Mupiban per day) based on calculations of dose divided by the entire body surface area, did not result in impaired fertility or impaired reproductive performance attributable to Mupiban.

14 CLINICAL STUDIES

The efficacy of topical Mupiban ointment in impetigo was tested in 2 trials. In the first, subjects with impetigo were randomized to receive either Mupiban ointment or vehicle placebo 3 times daily for 8 to 12 days. Clinical efficacy rates at end of therapy in the evaluable populations (adults and pediatric subjects included) were 71% for Mupiban ointment (n = 49) and 35% for vehicle placebo (n = 51). Pathogen eradication rates in the evaluable populations were 94% for Mupiban ointment and 62% for vehicle placebo.

In the second trial, subjects with impetigo were randomized to receive either Mupiban ointment 3 times daily or 30 to 40 mg per kg oral erythromycin ethylsuccinate per day (this was an unblinded trial) for 8 days. There was a follow-up visit 1 week after treatment ended. Clinical efficacy rates at the follow-up visit in the evaluable populations (adults and pediatric subjects included) were 93% for Mupiban ointment (n = 29) and 78.5% for erythromycin (n = 28). Pathogen eradication rates in the evaluable populations were 100% for both test groups.

Pediatrics

There were 91 pediatric subjects aged 2 months to 15 years in the first trial described above. Clinical efficacy rates at end of therapy in the evaluable populations were 78% for Mupiban ointment (n = 42) and 36% for vehicle placebo (n = 49). In the second trial described above, all subjects were pediatric except 2 adults in the group receiving Mupiban ointment. The age range of the pediatric subjects was 7 months to 13 years. The clinical efficacy rate for Mupiban ointment (n = 27) was 96%, and for erythromycin it was unchanged (78.5%).

15 REFERENCES

• Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-sixth Informational Supplement. CLSI document M100-S26. Clinical and Laboratory Standards Institute, 950 West Valley Rd., Suite 2500, Wayne, PA 19087, USA, 2016.
• Patel J, Gorwitz RJ, et al. Mupiban Resistance. Clinical Infectious Diseases. 2009; 49(6): 935-41.
• Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – Tenth Edition. CLSI document M07-A10. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.
• Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard – Twelfth Edition. CLSI document M02-A12. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.
• Finlay JE, Miller LA, Poupard JA. Interpretive criteria for testing susceptibility of staphylococci to Mupiban. Antimicrob Agents Chemother. 1997; 41(5):1137-1139.

16 HOW SUPPLIED/STORAGE AND HANDLING

Each gram of Mupiban Ointment USP contains 20 mg Mupiban, USP in a water-miscible ointment base.

Mupiban Ointment USP, 2% is supplied in 22-gram tubes.

NDC 68462-180-22 22-gram tube (1 tube per carton)

Store at 20° to 25°C (68° to 77°F).

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Advise the patient to administer Mupiban ointment as follows:

• Use Mupiban ointment only as directed by the healthcare provider. It is for external use only. Avoid contact of Mupiban ointment with the eyes. If Mupiban ointment gets in the eyes, rinse thoroughly with water.
• Do not use Mupiban ointment in the nose.
• Wash your hands before and after applying Mupiban ointment.
• Use a gauze pad or cotton swab to apply a small amount of Mupiban ointment to the affected area. The treated area may be covered by gauze dressing if desired.
• Report to the healthcare provider any signs of local adverse reactions. Mupiban ointment should be stopped and the healthcare provider contacted if irritation, severe itching, or rash occurs.
• Report to the healthcare provider or go to the nearest emergency room if severe allergic reactions, such as swelling of the lips, face, or tongue, or wheezing occur [see Warnings and Precautions ( 5.1)].
• If impetigo has not improved in 3 to 5 days, contact the healthcare provider.

Trademarks are the property of their respective owners.

Manufactured by:

Glenmark Pharmaceuticals Ltd.

Colvale-Bardez, Goa 403 513, India

Manufactured for:

Glenmark Pharmaceuticals Inc., USA

Mahwah, NJ 07430

Questions? 1 (888)721-7115

www.glenmarkpharma.com/usa

July 2017

Glenmark

Patient Information

Mupiban (mue-PIR-oh-sin)

Ointment

What is Mupiban ointment?

Mupiban ointment is a prescription medicine used on the skin (topical use) to treat a skin infection called impetigo that is caused by bacteria called Staphylococcus aureus and Streptococcus pyogenes. It is not known if Mupiban ointment is safe and effective in children under 2 months of age.

Who should not use Mupiban ointment?

Do not use Mupiban ointment if:

• you are allergic to Mupiban or any of the ingredients in Mupiban ointment. See the end of this Patient Information leaflet for a complete list of the ingredients in Mupiban ointment.

What should I tell my healthcare provider before using Mupiban ointment?

Before using Mupiban ointment, tell your healthcare provider about all of your medical conditions including if you:

• have kidney problems
• are pregnant or plan to become pregnant. It is not known if Mupiban ointment will harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if Mupiban ointment passes into your breast milk. You and your healthcare provider should decide if you can use Mupiban ointment while breastfeeding.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Do not mix Mupiban ointment with other lotions, creams, or ointments.

How should I use Mupiban ointment?

• Mupiban ointment is for use on the skin (topical). Do not get Mupiban ointment in your eyes, nose, mouth, or vagina (mucosal surfaces).
• Use Mupiban ointment exactly as your healthcare provider tells you to use it.
• Apply a small amount of Mupiban ointment, with a cotton swab or gauze pad, to the affected area 3 times each day.
• It is important that you take the full course of Mupiban ointment. Do not stop early because your symptoms may disappear before the infection is fully cleared.
• Wash your hands before and after applying Mupiban ointment.
• After applying Mupiban ointment, you may cover the treated area with a clean gauze pad, unless your healthcare provider has told you to leave it uncovered.
• Talk to your healthcare provider if your skin does not improve after 3 to 5 days of treatment with Mupiban ointment.
• If you are breastfeeding and use Mupiban ointment on your breast or nipple, wash the area well before breastfeeding your child.

What are the possible side effects of Mupiban ointment?

Mupiban ointment may cause serious side effects, including:

• severe allergic reactions. Stop using Mupiban ointment and call your healthcare provider or go to the nearest emergency room right away if you have any of the following signs or symptoms of a severe allergic reaction:

hives	trouble breathing or wheezing
swelling of your face, lips, mouth, or tongue	dizziness, fast heartbeat, or pounding in your chest
a rash over your whole body

• • eye irritation. Do not get Mupiban ointment in your eyes. If Mupiban ointment gets in your eyes, rinse your eyes well with water.
  • irritation in the area Mupiban ointment is used. Stop using Mupiban ointment and call your healthcare provider if you develop an irritation, severe itching, or a rash while using Mupiban ointment.
  • a type of diarrhea called clostridium difficile-associated diarrhea (CDAD). CDAD may happen in people who use or have used medicine to treat bacterial infections. The severity of CDAD can range from mild diarrhea to severe diarrhea that may cause death (fatal colitis). Call your healthcare provider or go to the nearest emergency room right away if you have diarrhea while using or after you stop using Mupiban ointment.
  • risk of absorption of polyethylene glycol through the skin. Mupiban ointment contains polyethylene glycol, which in large amounts can cause kidney damage. You should not apply Mupiban ointment to open skin wounds or damaged skin, especially if you have kidney problems.
  • increased risk of infection at IV (intravenous) sites. Mupiban ointment should not be used on skin that is near an IV (intravenous) site.

The most common side effects of Mupiban ointment include:

• • burning
  • stinging or pain
  • itching

These are not all the possible side effects of Mupiban ointment. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Mupiban ointment?

• Store Mupiban ointment at room temperature between 68°F to 77°F (20°C to 25°C).
• Keep Mupiban ointment and all medicines out of the reach of children.

General information about the safe and effective use of Mupiban ointment

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Mupiban ointment for a condition for which it was not prescribed. Do not give Mupiban ointment to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Mupiban ointment that is written for health professionals.

What are the ingredients in Mupiban ointment?

Active Ingredient: Mupiban

Inactive Ingredients: polyethylene glycol 400 and polyethylene glycol 3350

Trademarks are the property of their respective owners.

Manufactured by:

Glenmark Pharmaceuticals Ltd.

Colvale-Bardez, Goa 403 513, India

Manufactured for:

Glenmark Pharmaceuticals Inc., USA

Mahwah, NJ 07430

Questions? 1 (888)721-7115

www.glenmarkpharma.com/usa

July 2017

Glenmark

NDC 68462-180-22

Mupiban Ointment USP, 2% - 22 g

Mupiban pharmaceutical active ingredients containing related brand and generic drugs:

• Mupirocin

Mupiban available forms, composition, doses:

• Ointment; Topical; Mupirocin 2%

Mupiban destination | category:

• Human:
• Antibiotics
• Topical antibiotics

Mupiban Anatomical Therapeutic Chemical codes:

• D06AX09 - Mupirocin
• R01AX06 - Mupirocin

Mupiban pharmaceutical companies:

• Agio Pharmaceuticals

References

1. Dailymed."MUPIROCIN OINTMENT [GLENMARK PHARMACEUTICALS INC., USA]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
2. Dailymed."MUPIROCIN CALCIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
3. "Mupirocin". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Mupiban?

Depending on the reaction of the Mupiban after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Mupiban not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Mupiban addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

Review

sdrugs.com conducted a study on Mupiban, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Mupiban consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 25 here

The information was verified by Dr. Rachana Salvi, MD Pharmacology